Does CJC-1295 increase growth hormone?

It does so in animal models and in a limited human pharmacokinetic study. Whether that translates into safe

What is the difference between CJC-1295 with and without DAC?

The "with DAC" version has a longer half-life due to albumin binding but is associated with less physiological pulsatility. The "without DAC" form (Mod GRF 1-29) is shorter-acting. Neither is approved.

Is it safe to stack with ipamorelin?

There is no human safety data on such combinations. Stacking GH-releasing peptides is speculative and adds risk.

growth

CJC-1295

CJC-1295 is a synthetic growth hormone-releasing hormone (GHRH) analog that stimulates endogenous growth hormone release. It is widely marketed in the gray market but has no approved medical use and no published human randomized controlled trials supporting the marketed claims.

Ian Gauntt, RN BSN1 min readPreclinical

Aliases: CJC-1295 without DAC, Mod GRF 1-29

Educational content only — this is not medical advice. Nothing here is a recommendation to buy, obtain, or use CJC-1295. Talk to a licensed clinician before making health decisions.

What it is

CJC-1295 is a modified 29-amino-acid fragment of GHRH (also called sermorelin or Mod GRF 1-29). It binds to the GHRH receptor on somatotrophs in the pituitary to trigger pulsatile growth hormone release. The "without DAC" form lacks a drug affinity complex and therefore has a short half-life, requiring multiple daily injections.

What the evidence shows

Evidence is preclinical. In animal studies, CJC-1295 increases growth hormone and IGF-1 levels and can increase lean body mass in some rodent models. No published human RCT has evaluated the injectable peptide sold online for body composition, performance, or anti-aging. Claims of muscle gain, fat loss, and anti-aging in humans are extrapolated from animal data and user reports.

Risks & unknowns

Human safety data are lacking. Expected pharmacology includes elevated GH/IGF-1, which in excess can cause water retention, joint pain, insulin resistance, acromegaly-like changes, and theoretical cancer risk. Unregulated products carry additional purity and sterility risks.

Legal / regulatory status

CJC-1295 is not FDA-approved and is prohibited in sport by WADA under S2 (peptide hormones, growth factors, related substances and mimetics). It is illegal to market for human use.

FAQ

Does CJC-1295 increase growth hormone?: It does so in animal models and in a limited human pharmacokinetic study. Whether that translates into safe
What is the difference between CJC-1295 with and without DAC?: The "with DAC" version has a longer half-life due to albumin binding but is associated with less physiological pulsatility. The "without DAC" form (Mod GRF 1-29) is shorter-acting. Neither is approved.
Is it safe to stack with ipamorelin?: There is no human safety data on such combinations. Stacking GH-releasing peptides is speculative and adds risk.

References

Prolonged stimulation of growth hormone by CJC-1295 in rats (Endocrinologypreclinical
CJC-1295: growth hormone releasing factor analog (J Clin Endocrinol Metab, 2006)human pharmacokinetic study
WADA Prohibited List: S2 peptide hormonesregulatory